Emma E van der Toom
Overview
Explore the profile of Emma E van der Toom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hentschel A, van der Toom E, Vis A, Ket J, Bosschieter J, Heymans M, et al.
BJU Int
. 2020 Jun;
127(1):12-27.
PMID: 32539176
Objectives: To systematically summarise the available evidence on urinary bladder cancer (BC) mutation markers. Gene mutations are expected to provide novel biomarkers for urinary BC diagnosis. To date, evidence on...
2.
van der Toom E, Axelrod H, de la Rosette J, de Reijke T, Pienta K, Valkenburg K
Nat Rev Urol
. 2018 Nov;
16(1):7-22.
PMID: 30479377
Despite improvements in early detection and advances in treatment, patients with prostate cancer continue to die from their disease. Minimal residual disease after primary definitive treatment can lead to relapse...
3.
Chalfin H, Kates M, van der Toom E, Glavaris S, Verdone J, Hahn N, et al.
Urology
. 2018 Feb;
115:82-86.
PMID: 29432873
Objective: To investigate circulating tumor cells (CTCs) as biomarkers of urothelial carcinoma (UC). To date, the majority of work on this topic has utilized the CellSearch test, which has limited...
4.
van der Toom E, Groot V, Glavaris S, Gemenetzis G, Chalfin H, Wood L, et al.
Prostate
. 2017 Dec;
78(4):300-307.
PMID: 29285777
Introduction: Circulating tumor cells (CTCs) can provide important information on patient's prognosis and treatment efficacy. Currently, a plethora of methods is available for the detection of these rare cells. We...
5.
Chalfin H, Verdone J, van der Toom E, Glavaris S, Gorin M, Pienta K
Clin Genitourin Cancer
. 2017 Feb;
15(3):e477-e481.
PMID: 28153390
Introduction: Circulating tumor cells (CTCs) have great potential as circulating biomarkers for solid malignancies. Currently available assays for CTC detection rely on epithelial markers with somewhat limited sensitivity and specificity....
6.
van der Toom E, Verdone J, Jun C, Petrisor D, Lim S, de la Rosette J, et al.
Med Oncol
. 2017 Jan;
34(2):22.
PMID: 28058627
The cancer community continues to search for an efficient and cost-effective technique to isolate and characterize circulating cells (CTCs) as a 'real-time liquid biopsy'. Existing methods to isolate and analyze...
7.
Valkenburg K, Amend S, Verdone J, van der Toom E, Hernandez J, Gorin M, et al.
Oncotarget
. 2016 Sep;
7(43):69794-69803.
PMID: 27634877
Bone metastasis is a lethal and incurable disease. It is the result of the dissemination of cancer cells to the bone marrow. Due to the difficulty in sampling and detection,...
8.
van der Toom E, Verdone J, Gorin M, Pienta K
Oncotarget
. 2016 Aug;
7(38):62754-62766.
PMID: 27517159
Increasing evidence suggests that cancer cells display dynamic molecular changes in response to systemic therapy. Circulating tumor cells (CTCs) in the peripheral blood represent a readily available source of cancer...
9.
van der Toom E, Verdone J, Pienta K
Curr Opin Biotechnol
. 2016 Feb;
40:9-15.
PMID: 26900985
It has been reported that disseminated tumor cells (DTCs) can be found in the majority of prostate cancer (PCa) patients, even at the time of primary treatment with no clinical...